PATRYS Ltd Cash Flow Conversion Efficiency

Latest as of June 2025: -2.365x

PATRYS Ltd cash flow conversion efficiency. Based on the latest financial reports, PATRYS Ltd (PAB) has a cash flow conversion efficiency ratio of -2.365x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.73 Million ≈ $-1.23 Million USD) by net assets (AU$732.87K ≈ $518.56K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of PATRYS Ltd (2008–2025)

Cash flow conversion efficiency of PATRYS Ltd from 2008 to 2025. This chart illustrates how PATRYS Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for PATRYS Ltd for real-time trading data and today's change.

PATRYS Ltd Cash Flow Conversion Ratio Explained

PATRYS Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

PATRYS Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of PATRYS Ltd ranked by their cash flow conversion efficiency. Also see market cap of PATRYS Ltd for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
ASN Broker Public Company Limited
BK:ASN
0.027x
Fobi AI Inc
V:FOBI
0.070x
XiDeLang Holdings Ltd
KLSE:5156
-0.142x
Evion Group NL
AU:EVG
-0.122x
Myseum, Inc.
NASDAQ:MYSE
-0.159x
Llama Group S.A.
PA:ALLAM
0.411x
Cellectar Biosciences Inc
NASDAQ:CLRB
-0.438x
K.C. Metalsheet Public Company Limited
BK:KCM
0.042x

Annual Cash Flow Conversion Efficiency for PATRYS Ltd (2008–2025)

The table below shows the annual cash flow conversion efficiency of PATRYS Ltd from 2008 to 2025. Review PAB free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$732.87K
≈ $518.56K
AU$-1.77 Million
≈ $-1.26 Million
-2.421x -362.62%
2024-06-30 AU$3.47 Million
≈ $2.46 Million
AU$-1.82 Million
≈ $-1.28 Million
-0.523x +38.08%
2023-06-30 AU$6.84 Million
≈ $4.84 Million
AU$-5.78 Million
≈ $-4.09 Million
-0.845x -30.75%
2022-06-30 AU$13.43 Million
≈ $9.50 Million
AU$-8.68 Million
≈ $-6.14 Million
-0.646x -100.76%
2021-06-30 AU$12.04 Million
≈ $8.52 Million
AU$-3.88 Million
≈ $-2.74 Million
-0.322x +37.06%
2020-06-30 AU$4.88 Million
≈ $3.45 Million
AU$-2.50 Million
≈ $-1.77 Million
-0.512x -2789.46%
2019-06-30 AU$7.30 Million
≈ $5.16 Million
AU$-129.19K
≈ $-91.41K
-0.018x +93.81%
2018-06-30 AU$7.29 Million
≈ $5.16 Million
AU$-2.09 Million
≈ $-1.48 Million
-0.286x +40.32%
2017-06-30 AU$2.66 Million
≈ $1.88 Million
AU$-1.28 Million
≈ $-903.55K
-0.480x -13.93%
2016-06-30 AU$3.64 Million
≈ $2.57 Million
AU$-1.53 Million
≈ $-1.08 Million
-0.421x +59.39%
2015-06-30 AU$3.97 Million
≈ $2.81 Million
AU$-4.11 Million
≈ $-2.91 Million
-1.036x -153.21%
2014-06-30 AU$12.43 Million
≈ $8.80 Million
AU$-5.09 Million
≈ $-3.60 Million
-0.409x -67.78%
2013-06-30 AU$10.77 Million
≈ $7.62 Million
AU$-2.63 Million
≈ $-1.86 Million
-0.244x +19.13%
2012-06-30 AU$12.45 Million
≈ $8.81 Million
AU$-3.75 Million
≈ $-2.66 Million
-0.302x +20.56%
2011-06-30 AU$13.47 Million
≈ $9.53 Million
AU$-5.11 Million
≈ $-3.62 Million
-0.380x +18.00%
2010-06-30 AU$15.23 Million
≈ $10.78 Million
AU$-7.05 Million
≈ $-4.99 Million
-0.463x -13.05%
2009-06-30 AU$17.72 Million
≈ $12.54 Million
AU$-7.26 Million
≈ $-5.14 Million
-0.410x -26.26%
2008-06-30 AU$22.98 Million
≈ $16.26 Million
AU$-7.45 Million
≈ $-5.27 Million
-0.324x --

About PATRYS Ltd

AU:PAB Australia
Market Cap
$5.30 Million
AU$7.50 Million AUD
Market Cap Rank
#28378 Global
#1465 in Australia
Share Price
AU$0.02
Change (1 day)
-4.35%
52-Week Range
AU$0.02 - AU$0.05
All Time High
AU$0.07
About

Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and metastases that are associated wit… Read more